Literature DB >> 25589526

Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.

Matteo Pezzoli1, Maurizio Bona Galvagno1, Guido Bongioannini1.   

Abstract

We present a case of a woman who developed an oral squamous cell carcinoma (SCC) after being treated for a recurrent ovarian carcinoma with subtotal gastric resection and adjuvant pegylated liposomal doxorubicin (PLD). She received six cycles of PLD induction and maintenance therapy, which was continued for 5 years. She was free from disease at the following visits but 3 years later she developed SCC of her left inferior edentulous gums. The patient was negative for human papillomavirus and had never smoked in her life or had a history of alcohol use or any other environmental risk factors. PLD is known to accumulate in eccrine glands of the hands and the feet and in the oral mucosa, therefore causing skin toxicity and mucositis. It is conceivable that this specific biodistribution to the oral mucosa may be responsible for the onset of SCC. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589526      PMCID: PMC4307081          DOI: 10.1136/bcr-2014-204056

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.

Authors:  Matteo Morotti; Mario Valenzano Menada; Pier Luigi Venturini; Simone Ferrero
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-24       Impact factor: 4.481

2.  Aggressive squamous cell carcinoma of the oral tongue in a woman with metastatic giant cell tumor treated with pegylated liposomal doxorubicin.

Authors:  Ping Gu; Jennifer Wu; Mike Sheu; David Myssiorek; Richard Cohen
Journal:  Oncologist       Date:  2012

3.  Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?

Authors:  Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

Review 4.  Secondary malignancies following cancer chemotherapy.

Authors:  P Boffetta; J M Kaldor
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

5.  Two successive ocular malignancies in the same eye of a HIV-positive patient: a case report.

Authors:  Kalpana Babu; Krishna R Murthy; Subramanian Krishnakumar
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

6.  Osteosarcoma of the mandible--second cancer in a case of Hodgkin's lymphoma post-chemotherapy.

Authors:  Sumitava De; Suparna Ghosh; Dodul Mondal; Prabir K Sur
Journal:  J Cancer Res Ther       Date:  2010 Jul-Sep       Impact factor: 1.805

7.  Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.

Authors:  Ewa Jaworowska; Czesława Tarnowska; Jakub Lubiński; Pablo Serrano-Fernández; Tomasz Huzarski; Bogdan Górski; Bartlomiej Masojć; Jerzy Jakubiszyn; Aleksandra Korytowska; Andrzej Kram; Jerzy Rabczynski; Jan Lubiński
Journal:  Anticancer Res       Date:  2009-07       Impact factor: 2.480

8.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

9.  Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

Authors:  L Martín-Carbonero; R Palacios; E Valencia; P Saballs; G Sirera; I Santos; F Baldobí; M Alegre; A Goyenechea; J Pedreira; J González del Castillo; J Martínez-Lacasa; A Ocampo; M Alsina; J Santos; D Podzamczer; J González-Lahoz
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

Review 10.  Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.

Authors:  Rebecca Soloman; Alberto A Gabizon
Journal:  Clin Lymphoma Myeloma       Date:  2008-02
View more
  3 in total

1.  Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling.

Authors:  Fatouma Alimirah; Tanya Pulido; Alexis Valdovinos; Sena Alptekin; Emily Chang; Elijah Jones; Diego A Diaz; Jose Flores; Michael C Velarde; Marco Demaria; Albert R Davalos; Christopher D Wiley; Chandani Limbad; Pierre-Yves Desprez; Judith Campisi
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

2.  Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma.

Authors:  Valentina Coccè; Davide Farronato; Anna Teresa Brini; Carla Masia; Aldo Bruno Giannì; Giovanna Piovani; Francesca Sisto; Giulio Alessandri; Francesca Angiero; Augusto Pessina
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

3.  Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.

Authors:  Hidetaka Nomura; Kimihiko Sakamoto; Takeru Sugihara; Shuhei Okamoto; Yoichi Aoki; Terumi Tanigawa; Maki Matoda; Kohei Omatsu; Hiroyuki Kanao; Kazuyoshi Kato; Kuniko Utsugi; Yuko Sugiyama; Nobuhiro Takeshima
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.